2Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome [J]. Nature, 2004, 428(6982): 486.
3Man CB, Kwan P, Baum L, et aL Association between HLA-B*1502 allele and antiepileptic drug-induced cutane- ous reactions in Han Chinese [J]. Epilepsia, 2007, 48(5): 1015-1018.
4Lonjou C, Thomas L, Borot N, etal. A marker for Stevens- Johnson syndrome: ethnicity matters [J]. Pharmacogenom- ics J, 2006, 6(4): 265-268.
5Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersen- sitivity [J]. Pharmacogenomics, 2006, 7(6): 813-818.
6Locharernkul C, Loplumlert J, Limotai C, et al. Carbam- azepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population [J]. Epilepsia, 2008, 49(12): 2087-2091.
7Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japa- nese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis [J]. Pharmacogenomics, 2008, 9(11): 1617-1622.
8Chang CC, Too CL, Murad S, et al. Association of HLA- B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi- ethnic Malaysian population [J]. Int J Dermatol, 2011, 50(2).. 221-224.
9Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B*IS02 allele and carbamazepine-induced Stevens- Johnson syndrome among Indians [J]. Indian J Dermatol Venereol Leprol, 2009, 75(6): 579-582.
10Ozeki T, Mushiroda T, Yowang A, et aL Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population [J]. Hum Mol Gen- et, 2011, 20(5): 1034-1041.
